3rd generation glp 1 agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Understanding the Next-Gen Weight Loss

There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop, said senior author Ziyad Al-Aly, MD, a WashU Medicine clinical epidemiologist and chief of the Research and Development Service at the VA Saint Louis Health Care System

The investigators increased the pemvidutide dose gradually over the first 4 weeks to reach the 2.4-mg dose

Joel Habener and the Identification of GLP-1 Dr

2023;381:e074068

Fella understands that creating a positive experience with GLP-1 therapy is critical to patient success

Implications for Clinical Practice and Future Research At present, GLP-1 receptor agonists remain the primary evidence-supported pharmacologic option for adolescents with obesity